MedicalDevice Licensing.com
Pharmalicensing.com
Latest: Watch here for details of new products and services.
RSS Feeds
Advanced search

Login  Register

About Us
Pharmalicensing - Partnering solutions for the life sciences
 
Our Products
Overview
Partnering Search
Company Profiling
Deal Negotiation
PL Intelligence
Reports
Comparison
 
PL Intelligence
Overview
Industry news
Deals review
Press releases
Articles
 
Case Studies
See what others think about our service
 
Newsletter
Partnering update
Key reports
Subscribe
 
Quick Links
Profile now
Register now
Profiled companies
Featured events
Industry news
PR Newswire
Jobs
 
Contact Pharmalicensing
Send an email
Call us: +44 1904 520460
Request a callback
 
RSS Feeds
Keep up to date

Pharmalicensing
is a division of
UTEK Europe Ltd
UTEK Corporation
Companies

King Pharmaceuticals Canada Inc

King Pharmaceuticals  Canada Inc
Speciality Pharmaceutical Company seeking to improve the lives of patient by bringing products to market though in-licensing and acquisition (product and company).

The company in detail

Summary

King Pharmaceuticals is an S&P 500 Index company, seeks to capitalize on opportunities in the pharmaceutical industry through the development, including through in-licensing arrangements and acquisitions, of novel branded prescription pharmaceutical products in attractive markets and the strategic acquisition of branded products that can benefit from focused promotion and marketing and product life-cycle management. King Pharmaceuticals® began operations in January 1994, after purchasing the company's Bristol Tennessee facility and assuming contracts to manufacture prescription pharmaceutical products for such prominent companies as SmithKline Beecham Corporation, predecessor to GlaxoSmithKline, and Novartis. For the next ten years, King principally focused on the manufacture, acquisition, and marketing of previously approved products. Under new leadership, the company shifted its strategy to position itself to become a leading developer and acquirer of novel branded pharmaceutical products in later stages of development, focusing on three main therapeutic areas, cardiovascular/metabolics, neuroscience and hospital/acute care. King's labor force has grown from an initial 145 to approximately 2700 employees involved in every discipline of a major pharmaceutical company, including sales and marketing, research and development, regulatory affairs, quality management, and manufacturing. On September 7, 2006 - King Pharmaceuticals entered into a definitive asset purchase agreement and related agreements with Ligand Pharmaceuticals Incorporated to acquire rights to AVINZA®.

R&D

To view this information, you must subscribe to PL Intelligence.

Partnerships

To view this information, you must subscribe to PL Intelligence.

Deals

To view this information, you must subscribe to PL Intelligence.

Senior management

To view this information, you must subscribe to PL Intelligence.

Board of directors

To view this information, you must subscribe to PL Intelligence.

Clients in focus...

Get the Flash Player to see this rotator.

Partnering discussion free of charge
Press releases: Pharmalicensing current industry press releases.

© Copyright 1995-2009 Pharmalicensing, a division of UTEK Europe Ltd UTEK Corporation All rights reserved. Terms and Conditions | Contact us